The aim of the present study was to determine the drug survival during 2 years' follow-up in patients (n = 104) with active rheumatoid arthritis (RA) or spondyloarthropathy (SpA) who were treated with inXiximab as their Wrst biological anti-rheumatic drug in a single rheumatological center. According to the national guidelines, inXiximab was added to the treatment with combinations of traditional disease-modifying anti-rheumatic drugs (DMARD). Patients' records were analyzed at baseline and after 2 years of follow-up. The response to treatment was determined inadequate if the response was lower than ACR50 (American College of Rheumatology 50) in RA or the reduction of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was lower than 50% or 2 cm in SpA. Drug survival in inXiximab-treated patients after 2 years was 40%, and among those who continued with the therapy the prednisolone dose has been reduced by 52%. Discontinuation rate was 60% during 2 years of follow-up, where 7% achieved remission and 22% of the patients were regarded as poor responders. As much as 24% of the patients discontinued due to an adverse event, mainly infections and hypersensitivity reactions. Two drug-related leukopenias were diagnosed. In the present study, inXiximab therapy was initiated in RA or SpA patients who had active disease despite ongoing treatment with combinations of DMARDs. The drug survival with inXiximab was 40% after 2 years of follow-up. During the 2-year follow-up, 60% discontinued inXiximab treatment, mainly due to unsatisfactory or waning eYcacy or a severe adverse event.
Introduction
Tumor necrosis factor alpha (TNF ) modulator inXiximab has been shown to be eVective, antierosive and well tolerated in the treatment of rheumatoid arthritis (RA) [1] [2] [3] [4] and spondyloarthropathies (SpA) [5, 6] in clinical trials. It is routinely used in the everyday practice when traditional DMARDs are not suYciently eVective. Although inXiximab is generally safe and well tolerated, sometimes the treatment must be discontinued due to adverse events [1] [2] [3] [6] [7] [8] [9] [10] , mainly infections [11] [12] [13] [14] and hypersensitivity reactions [14, 15] . In addition, inadequate or waning eYcacy complicates drug survival in inXiximab-treated patients [8, 10, 14, 16] .
Many clinical trials use ACR20 as the criteria for continuation of inXiximab treatment, while in Finland the criteria for continuation has been set as ACR50 or a better response [17] . According to the national guidelines [17] , TNF antagonist treatment is indicated if the patient suVers from continuously active disease despite the treatment with combinations of traditional disease-modifying antirheumatic drugs (DMARD), including methotrexate. In addition, a TNF antagonist is usually added to the treatment with one or more DMARDs (see "Patients and methods"). In the present study, our interest was to analyze data from patients with active and refractory RA or SpA in a single rheumatological center, who received inXiximab as their Wrst biological treatment in combination with DMARDs on clinical grounds according to the national guidelines. We have recently published a 6 months' follow-up data, on RA and SpA patients receiving inXiximab as their Wrst biological drug, focusing on adverse events and other reasons for discontinuation of the treatment [18] . In the present study, we wanted to extend our analysis to drug survival up to 2 years in the same cohort. We deWned the number of patients who achieved at least 50% response and continued the treatment with inXiximab, the number of patients who discontinued the treatment and the reason for the discontinuation, and listed the adverse events leading to discontinuation of the treatment.
Patients and methods
In the present study, 104 patients with active RA or SpA were treated with inXiximab as their Wrst biological treatment in the Department of Internal Medicine, Center for Rheumatic Diseases of the Tampere University Hospital, Finland. Indication for the commencement of inXiximab treatment was based on the national recommendations [17] . The criteria to start inXiximab treatment for RA was that the patient suVered from continuously active RA [at least six swollen and tender joints, the duration of morning stiVness of at least 45 min, and/or erythrocyte sedimentation rate (ESR) ¸30 mmHg, and/or serum C-reactive protein (CRP)¸28 mg/l] despite treatment with combinations of traditional DMARDs including methotrexate and glucocorticoids [17] . In patients with ankylosing spondylitis (AS), the criteria to start inXiximab treatment were: (1) ineYciency of treatment with at least two nonsteroidal anti-inXammatory drugs (NSAIDs) over at least 3 months; (2) sulphasalazine (methotrexate if sulphasalazine contraindicated) or possibly other DMARDs had been ineVective, and (3) the patient had an active disease based on Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (¸4 cm) and on clinical grounds [acute sacroiliitis, elevated acute phase reactants, magnetic resonance imaging (MRI) Wndings]. In the other spondyloarthropathies, such as psoriatic arthritis (PsA) or inXammatory bowel disease (IBD)-associated arthritis, there were no deWned criteria to start treatment with biologicals, but the decision was made on clinical grounds by an experienced rheumatologist based on the severity of arthritis and the inXammatory axial disease, and on criteria available for RA and SpA.
InXiximab was given intravenously at a dose of 3 mg/kg in weeks 0, 2, 6 and every 8 weeks thereafter. The response determined whether the dose was elevated or lowered, or the infusion intervals shortened or lengthened. InXiximab was combined usually with methotrexate and in many cases with other DMARDs (mostly sulphasalazine or hydroxychloroquine) and low-dose prednisolone. The clinical response was carefully followed and registered by an experienced rheumatologist at each visit. In RA, the evaluation included ACR (American College of Rheumatology) response criteria [19] containing the number of swollen and tender joints, the physician's assessment of disease activity (VAS, Visual Analog Scale, 0-10 cm), patient's assessment of general health (VAS), pain (VAS) and HAQ (Health Assessment Questionnaire), and markers of acute phase activity (ESR and CRP). A treatment response lower than ACR50 was regarded as ineVective. In SpA, the clinical response included BASDAI and BASFI (Bath Ankylosing Spondylitis Functional Index), and the treatment was regarded as ineVective if the reduction in BASDAI index was lower than 50% or less than 2 cm.
The drug treatment in addition to inXiximab, i.e., glucocorticoids, DMARDs and NSAIDs, was documented. In the case of withdrawal, the reason (adverse event, ineYciency, remission or other reasons) was registered, and cases in which a severe adverse event caused the discontinuation of the treatment were reported to the National Agency of Medicines (NAM).
Results

Patients
In the present study, we analyzed drug survival in patients with active and refractory RA or SpA (n = 104) treated with inXiximab as their Wrst biologic drug at the Center for Rheumatic Diseases, Tampere University Hospital during the years 1999-2005. The mean age was 45 years (range 18-75), 64 patients (62%) were female and the mean disease duration was 12 years (range 0.8-52) ( Table 1) . One or more concomitant DMARDs in addition to inXiximab were used in 95% of the patients and 91% were receiving glucocorticoids in accordance with the national recommendations for inXiximab treatment (Table 1) . A total of 62 (60%) patients had RA, including seropositive disease in 37, seronegative in 15 and juvenile idiopathic arthritis (JIA) in 10 patients (Table 2) . A total of 42 (40%) patients had SpA with ankylosing spondylitis in 18, PsA in 8, seronegative oligoarthritis in 5, enteropathic arthritis in 4, reactive arthritis in 4 and sacroiliitis in 3 patients (Table 2) .
Drug survival in inXiximab-treated RA and SpA patients At the 2 years' time point, 41 (40%) patients had achieved at least a 50% treatment response and the treatment was still ongoing (Table 1 ). In nine of them, the inXiximab treatment was, however, transiently halted during the 2 years' follow-up due to a speciWc reason (one infection, Wve remissions, one migraine, one loss of eYcacy, and one adverse event from another drug). During 2 years of follow-up, the inXiximab treatment had been discontinued in 62 patients (60%) ( Table 1) . One patient moved to another district and was lost from the follow-up. After 2 years, 23 (37%) RA patients and 18 (44%) SpA patients were still continuing the inXiximab treatment (Table 2 ). In those patients in this group, the number receiving glucocorticoid treatment declined from 93 to 78% and the mean equivalent dose of prednisolone from 10.2 § 1.1 to 4.7 § 0.54 mg/day (mean § SEM p < 0.0001) during 2 years of inXiximab treatment.
The reasons for discontinuation of inXiximab treatment during the 2 years of follow-up are shown in Table 3 . During the 2 years' follow-up, 14 patients achieved remission lasting at least 6 months. However, 7 out of the 14 patients re-initiated inXiximab treatment during the follow-up due to disease activation, and thus 7 patients were still in remission without inXiximab treatment at the 2 years' time point.
The treatment was withdrawn from 23 (22%) patients due to poor eYcacy. Six patients discontinued the treatment already during the Wrst 7 months because an adequate Lack of eYcacy 23 37 Adverse event 25 40 Other reasons 7 11
Total 62 100 response was not attained. Seventeen patients, who initially exhibited an appropriate response were forced to discontinue due to decreasing eYcacy. In 25 (24%) patients, inXiximab was discontinued due to an adverse event (Table 4) . Of the adverse events, 9 were infections and 14 were hypersensitivity reactions. Two patients discontinued inXiximab treatment due to leukopenia. In Wve patients, inXiximab was discontinued for other reasons, i.e., intention to conceive (n = 2), technical diYculties in vein cannulation (n = 2) and maxillary sinus operation (n = 1). Two patients died during the follow-up, one after cerebral infarction and one after myocardial infarction.
Infections
Nine patients with infections were compelled to discontinue inXiximab treatment during the 2 years' follow-up. Most of these infections appeared during the Wrst year, and only one thereafter (after 22 months of treatment). Five of the nine infections were pneumonias. One pneumonia patient suVered for several months from Xuctuating fever and dyspnea, and she was eventually diagnosed to have mediastinal tuberculosis.
Two cases of septic arthritis appeared during the followup, one patient with arthritis in the ankle joint caused by Staphylococcus aureus and another with arthritis in the knee caused by Staphylococcus species. One patient had a generalized infection with elevated CRP (145 mg/l) with no clinically evident infection focus being detected (Table 4) . One 75-year-old female patient suVered from an asymptomatic recurrent urinary tract infection and inXiximab treatment was discontinued.
Hypersensitivity reactions
Of the 25 adverse events that required the discontinuation of the inXiximab treatment, 14 were hypersensitivity reactions (Table 4) , including acute infusion reactions such as urticaria, rash, itching or edema in 11 and delayed hypersensitivity reactions in 3 patients. All hypersensitivity reactions were reduced after discontinuation of the inXiximab infusions and glucocorticoid treatment. Three patients did not receive ongoing glucocorticoid treatment at the time of the hypersensitivity reaction.
Other adverse events
Two patients developed leukopenia related to inXiximab and the treatment was discontinued. In one 58-year-old patient, with neutrophils 1.4 £ 10 9 /l, conventional DMARDs (sulphasalazine and methotrexate) were Wrst discontinued without improvement. Discontinuation of inXiximab infusions resulted in a favorable response and leukocyte levels became normalized. Another patient experienced recurrent leukopenia (neutrophils 1.1 £ 10 9 /l). Discontinuation of conventional DMARDs had no eVect, and leukopenia was only relieved after discontinuation of the inXiximab treatment.
Discussion
The treatment of rheumatic diseases with biologicals in Pirkanmaa Health Care District, including the city of Tampere (serving a population of about 500,000), is concentrated at the Center for Rheumatic Diseases, Tampere University Hospital. In the present study, all the patients (n = 104) treated with inXiximab as their Wrst biological treatment for active RA or SpA according to the national guidelines during 1999-2005 in the Center for Rheumatic Diseases, were analyzed. InXiximab treatment was started for patients with active disease according to the discretion of an experienced rheumatologist, not as a randomized enrollment in a clinical trial. Thus, this analysis of the patient records provided data of the outcomes of inXiximab treatment in everyday practice at one rheumatological center.
The main goal in the treatment of active RA is to achieve and maintain remission with a combination of anti-rheumatic drugs [20, 21] . According to the national guidelines, inXiximab treatment is added to a combination DMARD therapy when patients have severe and refractory RA despite active treatment with traditional DMARDs. Contrary to the situation in randomized clinical trials, the patients in the present survey had severe and aggressive disease despite ongoing treatment with combinations of two or more DMARDs (not only MTX, which is the case in most randomized clinical trials with TNF inhibitors). In addition, the doses and numbers of glucocorticoids and NSAIDs were adjusted by the treating rheumatologist.
In the present study, we were able to retrieve patient records during the 2 years' follow-up from all patients who started the treatment with inXiximab, except for one subject who moved to another district. A signiWcant loss of patients during follow-up is quite a common phenomenon in many, especially observational, studies [22] [23] [24] . Concomitant DMARDs, especially methotrexate, when combined with biological treatment, enhance compliance to the treatment [25] and this may have inXuenced the very good adherence to the treatment also in the present survey. Combination therapy with methotrexate and inXiximab achieved a better response than methotrexate or inXiximab as monotherapy [2] [3] [4] . As mentioned previously, combination therapy with two or more DMARDs is widely used in Finland [20, 21] and a biological drug is frequently used to supplement combination DMARD therapy. In our previous study, we have CyA 300 mg/day SSZ 3,000 mg/day shown that in patients with refractory RA or SpA, the addition of etanercept or adalimumab to a combination of traditional DMARDs resulted in good, as well as a favorable treatment response, during 12 months' follow-up [26] . In the initial clinical randomized studies, Maini et al. [1] reported continuation rates up to 91% with ACR20 criteria after 30 weeks of inXiximab treatment depending on the dose and infusion intervals. In the study of Lipsky et al. [2] , a continuation rate of 79% was reported after 54 weeks of treatment. In observational studies, continuation rates are usually lower than in clinical randomized trials; 66% of the patients continued inXiximab infusions after 1 year [8] , and after 2 years' intervention 67% [9] and 73% [10] drug survival rates were reported. In the study of Buch et al. [14] only 27 out of 174 patients (16%) continued inXiximab treatment at the 24 months' time point. In the present study, 40% of the patients continued with inXiximab treatment after the 2 years' follow-up since they had achieved at least a 50% response without any severe adverse event or other reason requiring discontinuation of the treatment. In addition, 7 (7%) of 104 patients had discontinued inXiximab treatment due to remission.
In the present study, the continuation rate was 35% in RA patients and 44% in SpA patients. Although the diVerence was small, it conWrms the results obtained in previous studies. In a Spanish study, SpA patients had a 33% lower probability to discontinue the biologicals than RA patients [27] . Recently, Heiberg et al. [28] reported a higher continuation rate among patients with AS or PsA versus RA patients. In some clinical trials, inXiximab has been given at higher doses and/or shorter intervals to patients with SpA than in patients with RA [6, 7] . In the present study, inXiximab treatment was started at a dose of 3 mg/kg also in SpA patients and, if needed, the dose was increased and/or the infusion interval was adjusted in conjunction with the response. Accordingly, Braun et al. [7] concluded in their review that often a dose of 3 mg/kg is adequate also in SpA patients. However, there are data showing that increasing the inXiximab dose in SpA patients after 36 weeks of treatment from 5 to 7.5 mg/kg achieved no better eYcacy [6] .
The response to inXiximab treatment is evident already after 2 weeks of treatment, when over 50% of the RA patients have been reported to achieve ACR20 response [1] . There is probably some variation in the onset time of the response, and the eVect of the drug treatment can also wane with time. It was recently reported that in RA an increase in frequency of infusions may contribute to a more constant eVect than an increase in the dose [29] . In the study of Figueiredo et al. [16] , nearly 40% of the RA patients required an increase of the dose or a shortening of the interval between the inXiximab infusions or both to maintain relief of symptoms. In the present study, the average discontinuation time among the 23 patients with an inadequate response was 11 months after treatment initiation. According to the patients' records, 6/23 patients discontinued the treatment due to inadequate response during the Wrst 7 months, and 17/23 patients had an appropriate response at the beginning, but discontinued the treatment later because of waning eYcacy. Buch et al. [14] reported also that some patients could not maintain an already achieved response at later time points. In observational studies, the rate of discontinuation due to ineYcacy varies between 9.2 and 11% [8, 10, 16] . In clinical studies, discontinuation rates due to ineYcacy are around 10% [1, 2] . It is worth noticing that the continuation criteria in those studies have been mostly set as ACR20 and not ACR50 as in the present study, which is the clinical practice in Finland.
The formation of antibodies against inXiximab has been reported in clinical trials [1, 3] , and anti-inXiximab antibodies are more often found in patients with reduced response [30] . In addition, there is also evidence of the association between antibody formation and increased inXiximab clearance [31] . In the present study, antibodies against inXiximab were not measured. It is possible that the dissipating eYcacy was due to decreased concentrations of active inXiximab as a result of the formation of inXiximab-antibody complex or to diVerences in the metabolism of inXiximab in individual patients [32] .
In the present study, only those adverse events that led to discontinuation of inXiximab treatment were registered. Those were serious and often required either medical treatment or hospitalization. During the 2 years' follow-up, 24% of all patients were compelled to discontinue the medication due to adverse events. Infection was responsible for discontinuation of the treatment in 9% of the patients. In RA, there is an increased risk for infections [33, 34] . Traditional DMARDs have been reported to further elevate the risk [35] [36] [37] , but there are also contradictory Wndings [38] . Biologicals have also a tendency to increase the risk of infections [11, 39, 40] in RA patients. We observed in the present study a higher number of infections, which caused discontinuation of treatment during the Wrst year of treatment than in the second year. These data are in agreement with the results of Curtis et al. who reported a fourfold greater risk of infections during the Wrst 6 months of inXiximab treatment [39] . The most frequently occurring severe infections during inXiximab treatment are pulmonary, skin, soft tissue, joint and bone infections, and also septic infections are slightly more probable in RA patients treated with biological agents than in those treated with conventional DMARDs [11] [12] [13] 40] . Oral glucocorticoids have also been reported to elevate the risk of infections in patients with RA even at a dose less than 5 mg/day [35, 37, 38] . In active and severe RA or SpA, the use of biologicals in addition to combinations of DMARDs and oral glucocorticoidsis is probably associated with a high risk for infections and this should be taken into account clinically and when interpreting the results of the present study.
Hypersensitivity reactions appear to be related to inXiximab infusions quite often, but these are usually benign. In previous reports, hypersensitivity reactions have been a notable reason for discontinuation of inXiximab treatment, and they have most frequently occurred during the second to fourth infusion [14, 15] manifesting as urticaria, rash, itching and dyspnea. In the clinical study of Maini et al. [1] , hypersensitivity reactions appeared most commonly during the Wrst infusion. In our study, 13% of the patients had to discontinue inXiximab treatment due to a hypersensitivity reaction and half of these reactions occurred during the Wrst 6 months. In the present study, three patients with a hypersensitivity reaction did not receive glucocorticoid treatment in addition to the inXiximab and DMARDs. Augustsson et al. [41] reported that daily low-dose glucocorticoids lowered the risk of treatment-limiting infusion reactions to inXiximab.
In previous studies, only a few cases of leukopenias have been reported [9, [42] [43] [44] . In the present study, two patients developed leukopenia during the 2 years of follow-up. In a recent analysis of 1,440 patients with rheumatic disease who were treated with a biological drug, four patients with leukopenias were reported [45] .
In the present study, RA and SpA patients with active disease despite ongoing treatment with combinations of DMARDs were treated with inXiximab as their Wrst biological drug. Drug survival after 2 years of follow-up was 40%, when ACR50 (or 50% reduction in BASDAI) was set as the response criteria. As compared to our previous results with 6 months' follow-up [18] , drug survival decreased, mainly due to waning eYcacy and an increasing number of adverse events. Infections and hypersensitivity reactions were the most common adverse events, which were responsible for the discontinuation of treatment. In addition, two patients with drug-related leukopenia were diagnosed.
